Judson Althoff, CEO of the commercial business at Microsoft, announced the next phase of enterprise-level AI features for 365 Copilot, further supporting companies in transitioning to an AI-first 'frontier transformation' operational model.

Microsoft 365 Copilot is being upgraded from an assistive tool to a built-in AI agent capability, helping users complete tasks and truly drive work outcomes.

Through close collaboration with Anthropic, Microsoft introduced core technology supporting Claude Cowork into Microsoft 365 Copilot, and launched Copilot Cowork to support long-duration, multi-step complex workflows.

Agent 365 will be officially released on 1 May, priced at US$15 per user. Agent 365 enables IT and security managers to observe, manage, govern, and protect the entire enterprise's AI agents on a single platform, utilizing the same infrastructure, applications and security protections currently used for employee management.
~

AASTOCKS Financial News
Website: www.aastocks.com

Apple (AAPL.US) increased its iPhone production in India by approx. 53% last year, with the current production in India accounting for one-quarter of its total output, aiming to mitigate the impact of US tariffs, Bloomberg quoted sources as saying.

It is reported that Apple produces approx. 220 million to 230 million iPhones globally each year, and assembled about 55 million iPhones in India last year, up from 36 million units a year earlier.
~

AASTOCKS Financial News
Website: www.aastocks.com

The Iran war will end very soon, US President Donald Trump stated on Monday. Oil prices wildly fluctuated on Monday, with New York oil futures once peaking near USD120 before reverting down by 5% and returning to USD86.

US stocks opened lower on Monday but turned north sequentially, with all three major indices closing higher. The DJIA opened 130 points lower and at one point tumbled as much as 886 points before steadily climbing, with a peak/trough volatility of 1,260 points. It ultimately closed at 47,740, up 239 points or 0.5%. The S&P 500 added 55 points or 0.8% to 6,795. The Nasdaq rallied 308 points or 1.4% to 22,695.

Semiconductor stocks advanced, with Broadcom (AVGO.US) leaping over 4%, and Micron (MU.US) and AMD (AMD.US) soaring 5%. NVIDIA (NVDA.US) jumped up more than 2%. Alphabet (GOOG.US) also increased by over 2%.

Oil and defense stocks closed lower against the market trend, with ExxonMobil (XOM.US), Chevron (CVX.US), and Lockheed Martin (LMT.US) all declining. Airlines initially plummeted but later rebounded, with United Airlines (UAL.US), Delta Air Lines (DAL.US), and American Airlines (AAL.US) swelling more than 2%.
~



AASTOCKS Financial News
Website: www.aastocks.com

SHENZHEN, China, March 9, 2026 /PRNewswire/ -- RoboSense (2498.HK), an AI-driven robotics technology company, today announced that its cutting-edge thousand-beam-level digital LiDAR EM4 and fully solid-state digital LiDAR E1 have been selected for the Robotaxi GXR, co-developed by WeRide and Farizon New Energy Commercial Vehicle Group (a Geely subsidiary). The fleet of Robotaxi GXR is scheduled to begin rolling off the production line in Q3 2026, with a planned delivery of 2,000 units destined for both domestic and international markets.

Redefining L4 Perception with Thousand-Beam-Level Digital LiDAR

The Robotaxi GXR is equipped with the latest autonomous driving suite, GEN8. At the core of GEN8 is WeRide's self-developed Sensor Suite 8.0 (SS8.0), which includes RoboSense's  thousand-beam-level digital LiDAR EM4, as the main LiDAR, and thefully solid-state digital blind-spot LiDAR E1, ensuring safety and reliability during operation.

EM4, the Main LiDAR Capable of Thousand-Beam-Level Customization: Launched in early 2025 as the world's first digital LiDAR, the EM4 is now customizable with up to 2,160 beams. With a 17x increase in point cloud density and a detection range of up to 600 meters, the EM4 enables the Robotaxi GXR to identify hazards earlier, gaining over 70% more reaction time for decision-making in high-speed driving scenario.

E1, the Fully Solid-State Blind-Spot LiDAR: Featuring a wide 120° x 90° Field of View (FoV), the E1 is the industry's only mass-produced, automotive-grade solid-state digital LiDAR specifically designed to eliminate near-field blind spots.

The "EM4 for Main LiDAR + E1 for Blind-Spot LiDAR" configuration serves as an optimal choice for Robotaxi. This setup provides a seamless blend of long-range precision and 360-degree near-field coverage, ensuring reliable performance even in extreme weather conditions like heavy rain or dense fog.

Scaling Global Autonomous Mobility

RoboSense remains committed to accelerating the global deployment of Level 4 (L4) autonomous driving. As of January 2026, WeRide's Robotaxi GXR global fleet reached 1,023 vehicles. With the 2,000 newly upgraded GXR units delivering this year - empowered by the top-of-class digital LiDAR solutions from RoboSense, WeRide's operational fleet will exceed 2,600 Robotaxis globally.

Currently, WeRide operates commercial services in major cities including Abu Dhabi, Dubai, Riyadh, Beijing, and Guangzhou.

RoboSense currently maintains a partnership coverage of over 90% among the world's leading L4 autonomous driving companies, solidifying its role as the primary perception backbone for the global Robotaxi evolution.

SHANGHAI, March 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the commercial launch of VELSIPITY^® (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated Hospital of Sun Yat-sen University, marking a milestone in patient access in the region. As a once-daily oral therapy with sustained efficacy, a favorable safety profile, and the ability to achieve deep mucosal healing, VELSIPITY^® offers a novel treatment option for patients with moderately to severely active ulcerative colitis (UC), supporting long-term disease control and improved outcomes.

VELSIPITY^® is a next-generation, highly selective S1P receptor modulator with best-in-disease potential and strong first-line treatment recommendations in leading international guidelines. China's National Medical Products Administration (NMPA) has approved VELSIPITY^® on February 2, 2026, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

"With the first prescription now issued, VELSIPITY^® is being incorporated into routine clinical practice, providing physicians with an innovative treatment option for patients living with UC who continue to face ongoing disease challenges, " said Prof. Chen Minhu, Academic Leader of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University. "Results from multiple global clinical studies have demonstrated that VELSIPITY^® delivers meaningful clinical benefits, including rapid onset of action, long-lasting clinical remission, steroid-free remission, and deep mucosal healing, with a favorable safety profile. In the ENLIGHT UC study, the largest Asian multicenter Phase 3 clinical study, the clinical remission rate at week 40 of the maintenance period reached 48.1%, and the deep mucosal healing rate reached 51.9%, with an endoscopic mucosal normalization rate of 45.5%^[1]. These findings demonstrate VELSIPITY^®'s potential to improve long-term disease outcomes and reduce the risk of relapse and disease progression.

Results from the ELEVATE UC open-label extension demonstrate continuous treatment with VELSIPITY^® for up to 3 years resulted in 86.8% of patients achieving a clinical response among the observed cases, with both clinical remission and mucosal healing rates maintained at approximately 60%^[2]. Safety data extending up to five years from the global clinical program further confirm that VELSIPITY^® is well tolerated and maintains a favorable and stable safety profile^[3].

Under the 'Hong Kong and Macao Drug and Medical Devices Transit' policy, VELSIPITY^® has been introduced into clinical use in the Greater Bay Area, where real-world outcomes have demonstrated efficacy and safety consistent with those observed in clinical trials. We expect VELSIPITY^® to play an important role in optimizing UC management and advancing treatment toward the goal of mucosal healing, benefiting more patients."

Ulcerative colitis is a chronic, relapsing, non-specific inflammatory bowel disease characterized by symptoms such as mucus and blood in the stool, abdominal pain, diarrhea, and rectal tenesmus, which can significantly impact patients' daily lives and long-term health. In China, both the incidence and prevalence of UC are increasing, with a clear trend toward younger patients. There remains a critical need for therapies that offer sustained and comprehensive disease control.

"We are pleased to see that VELSIPITY^® achieved its first prescription in Mainland China just one month after approval, making this potentially best-in-disease therapy clinically available to a broader population of patients living with UC. This milestone underscores our ability to efficiently translate cutting-edge global therapies into clinical practice," said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "UC is an incurable disease, and the patient population is projected to grow from approximately 0.98 million in 2025 to 1.50 million by 2031 in China^[4],[5]. Patients require long-term management to maintain disease control.

Early achievement of mucosal healing is recognized as a key treatment goal, as it can significantly reduce rates of disease relapse, hospitalization, surgery, and the risk of progression to colorectal cancer. VELSIPITY^® addresses this need by targeting intestinal inflammation at its source and promoting mucosal healing, while offering a favorable profile of efficacy and safety, along with the convenience of an oral, once-daily regimen, supporting sustained disease management and improving patients' quality of life.

Everest has built a proven platform for the commercialization of innovative medicines, integrating scientific and commercial insights with coordinated access, medical, marketing, and sales (A2MS). We are confident in accelerating the rollout of VELSIPITY^® through multi-channel access, diversified patient support programs, and innovative reimbursement solutions. And we will work to secure inclusion of VELSIPITY^® in the National Reimbursement Drug List, further enhancing patient access and affordability."

In 2024 and 2025, VELSIPITY^® was included in the Catalogues of Guangdong Province on Drugs and Medical Devices from Hong Kong and Macao in Urgent Clinical Use in Nine Mainland Municipalities of the Guangdong-Hong Kong-Macao Greater Bay Area, making it available at designated hospitals across the region. To support long-term supply and commercialization, Everest launched the localized production project for VELSIPITY^® at its Jiashan manufacturing site in March 2025, strengthening its supply capabilities for Greater China and other Asian markets.

VELSIPITY^® has been strongly recommended as a first-line treatment for moderately to severely active ulcerative colitis in both the American Gastroenterological Association (AGA) Clinical Practice Guideline and the American College of Gastroenterology (ACG) Clinical Guideline Update, reflecting strong recognition of its efficacy and safety by leading international academic societies.

The approval of VELSIPITY^® in China was supported by results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12)⁶, which demonstrated statistically significant improvements in clinical remission and mucosal healing, along with a favorable safety profile. The ENLIGHT UC study is the largest Phase 3 trial of moderately to severely active UC in Asia completed to date, with 340 eligible subjects randomized to treatment with VELSIPITY^® or placebo. The study results showed that, VELSIPITY^® demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints during both the 12-week induction period and the 40-week maintenance period. The safety profile of VELSIPITY^® was consistent with previous studies, with no new safety signals observed. ELEVATE UC 52 and ELEVATE UC 12 are randomized, double-blind, placebo-controlled global phase 3 pivotal studies, which further demonstrate the positive benefit-risk profile of VELSIPITY^®. 

References:

1. K. Wu, et al. Lancet Gastroenterol Hepatol. 2025 Sep 30:S2468-1253(25)00198-0. 
2. B E Sands, et al. ECCO 2026. Abstract ID: jjaf231.774.
3. D.T. Rubin, et al. ECCO 2026. Abstract ID: jjaf231.1256.
4. Shao B, et al. Front Public Health. 2022 Oct 25;10:1032679.    
5. Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727. 
6. Sandborn WJ, et al. Lancet. 2023 Apr 8;401(10383):1159-1171.

About VELSIPITY^® (etrasimod arginine tablets)
VELSIPITY^® is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds to S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Japan, Australia, Singapore, UK, Switzerland, Israel, Turkey, India, Hong Kong SAR, Macao SAR and Mainland China for VELSIPITY^® in ulcerative colitis, as well as in additional countries. 

About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.

Forward-Looking Statements
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

上海 2026年3月9日 /美通社/ -- 雲頂新耀（HKEX 1952.HK）是一家專注於創新藥研發、臨床開發、製造及商業化的生物製藥公司，今日宣佈維適平^®（精氨酸艾曲莫德片, VELSIPITY^®）中國大陸首張處方於中山大學附屬第一醫院開出，標誌著該創新療法正式進入中國臨床應用階段。作為一款可實現深度黏膜癒合、並在長期治療中展現良好療效與安全性的口服藥物，維適平^®為中重度潰瘍性結腸炎（UC）患者提供了創新治療選擇，開啟深度黏膜癒合與長期疾病控制的全新治療篇章。

維適平^®是一款每日口服一次的新一代高選擇性S1P受體調節劑，具備最佳藥物（best-in-disease）潛質，已獲得國際權威指南強烈推薦，成為以深度黏膜癒合為目標的創新口服治療的一線治療選擇。2026年2月2日，中國國家藥品監督管理局批准了維適平^®的新藥上市許可申請，用於治療對傳統治療或生物制劑應答不充分、失應答或不耐受的中度至重度活動性潰瘍性結腸炎成人患者。

中華醫學會消化病學分會前任主任委員、炎症性腸病學組組長、中山大學附屬第一醫院消化內科學術帶頭人陳旻湖教授表示：「維適平^®此次首張處方的開具，標誌著這款創新口服新藥正式進入臨床實踐，為長期受疾病困擾的患者帶來更便捷、高效的治療新選擇。

多項全球臨床研究結果證實，維適平^®療效顯著，尤其在快速起效、實現無激素緩解及深度黏膜癒合方面具有明顯臨床優勢，同時安全性良好。在迄今完成的最大規模針對中重度UC患者的亞洲多中心 III 期臨床研究（ENLIGHT UC）中，維適平^®維持治療40周，臨床緩解率為48.1%，深度黏膜癒合率為51.9%，內鏡正常化率為45.5% ^[1]。數據顯示，維適平^®可實現強效深度黏膜癒合，從而改善疾病長期預後，並有助於降低復發及癌變風險。

全球Ⅲ期ELEVATE研究的一項開放標籤擴展研究數據證實，持續維適平^®治療3年，在觀察病例中，86.8%患者實現臨床應答，臨床緩解率和黏膜癒合率均維持在約60%水平^[2]。全球臨床研究隨訪5年的數據進一步表明其穩定且良好的安全性特徵，整體耐受性良好^[3]。

維適平^®的廣泛可及，有望進一步優化潰瘍性結腸炎的臨床管理路徑，推動疾病治療向更高水平發展，實現黏膜癒合的治療目標，惠及更多患者。」

潰瘍性結腸炎是一種病因尚不明確、易復發的慢性腸道炎症性疾病。近年來，中國潰瘍性結腸炎發病率和患病率持續上升。該疾病臨床表現為黏液血便、腹痛、腹瀉、裡急後重等症狀，嚴重影響患者的長期生活質量。因此，臨床亟需實現更加穩定、持久的疾病控制。

雲頂新耀首席執行官羅永慶表示：「非常高興看到維適平^®在獲批後僅用一個月就實現中國大陸首張處方的成功落地，惠及更廣泛的潰瘍性結腸炎患者。這一里程碑彰顯我們將國際前沿創新療法快速引入中國臨床實踐的實力。

中國潰瘍性結腸炎發病率和患病率不斷增加，並呈現年輕化趨勢，預計患者人數將由2025年的約98萬增長至2031年的約150萬^[4]，[5]。潰瘍性結腸炎目前仍無法治癒，患者需長期用藥維持疾病控制。作為一款治療潰瘍性結腸炎的創新一線治療藥物，維適平^®兼具『療效、安全性及方便性』三重優勢，為患者提供長期疾病控制與生活質量改善的保障。

黏膜癒合是當前潰瘍性結腸炎的治療目標，盡早實現可大幅降低患者疾病復發率、住院率、手術率和癌變風險。維適平^®可從源頭控制腸道炎症，促進黏膜癒合，填補了中重度潰瘍性結腸炎治療領域的空白。

雲頂新耀已建立經過驗證的以『科學及商業洞察驅動的准入、醫學、市場、銷售一體化協同（A2MS）』為核心的創新藥商業化運營平台，我們對加速推進維適平^®的商業化進程充滿信心，將通過構建多渠道准入體系，提供多元化患者援助項目和創新支付方案，並將全力推動維適平^®納入國家醫保目錄，提升該藥物的可及性和可負擔性，以滿足巨大的臨床需求。」

維適平^®於2024年和2025年被納入粵港澳大灣區內地9市臨床急需進口港澳藥品醫療器械目錄（文件中名稱為「伊曲莫德」），在大灣區率先實現臨床應用。為進一步保障產品供應與商業化落地，雲頂新耀已於2025年3月啟動維適平^®在嘉善工廠的本地化生產建設項目，支持其在大中華區及其他亞洲市場的持續供應。

同時，美國胃腸病學協會（AGA）臨床實踐指南與美國胃腸病學會（ACG）臨床指南均強烈推薦維適平^®作為中重度潰瘍性結腸炎的一線用藥，充分體現國際權威學術機構對其療效與安全性的高度認可。

維適平^®的新藥上市許可申請獲中國國家藥品監督管理局批准是基於亞洲多中心III期註冊臨床ENLIGHT UC研究（ES101002）的結果和全球III期註冊研究ELEVATE UC⁶（包括ELEVATE UC 52和ELEVATE UC 12研究）的結果。ENLIGHT UC研究是迄今完成的最大規模亞洲中重度活動性潰瘍性結腸炎患者的III期註冊臨床研究，總計納入340名患者。在12周誘導期及40周維持期治療中，維適平^®治療組在所有主要和次要療效終點上均達到統計學顯著性與臨床意義，且安全性良好。ELEVATE UC III期註冊研究中的ELEVATE UC 52和ELEVATE UC 12是兩項隨機、雙盲、安慰劑對照臨床研究，均達到了所有主要和關鍵次要終點，安全性特徵與既往研究一致。

參考文獻：

1. K. Wu, et al. Lancet Gastroenterol Hepatol. 2025 Sep 30:S2468-1253(25)00198-0. 
2. B E Sands, et al. ECCO 2026. Abstract ID: jjaf231.774.
3. D.T. Rubin, et al. ECCO 2026. Abstract ID: jjaf231.1256.
4. Shao B, et al. Front Public Health. 2022 Oct 25;10:1032679.     
5. Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727. 
6. Sandborn WJ, et al. Lancet. 2023 Apr 8;401(10383):1159-1171.

關於維適平^®(精氨酸艾曲莫德片，VELSIPITY^®)

維適平^®是一種每日口服一次的高選擇性鞘氨醇-1-磷酸 (S1P) 受體調節劑，採用優化的藥理學設計，與S1P受體1、4和5結合。維適平^®目前已在美國、歐盟、加拿大、日本、澳大利亞、英國、瑞士、以色列、土耳其、印度以及中國澳門、新加坡、中國香港和中國大陸獲得新藥上市批准。

關於雲頂新耀

雲頂新耀是一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司，致力於滿足全球市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業擁有深厚的專長和豐富的經驗。公司在浙江嘉善擁有具備商業化規模的全球生產基地，並嚴格按照國家藥品監督管理局（NMPA）和歐洲藥品管理局（EMA）的GMP要求及世界衛生組織（WHO）PQ標準建設。

公司聚焦自身免疫、眼科、急重症及CKM（心血管、腎臟及代謝）等疾病治療領域，已打造集全渠道商業化體系與藥品全生命週期商業化能力於一體的商業化平台，並以擁有全球權益的自研mRNA平台為基礎，持續推進mRNA in vivo CAR-T與mRNA腫瘤疫苗等現有管線，同時通過引進及生態孵化潛力平台，拓展研發能力，同時強化全球化佈局，加快國際化發展進程。更多信息，請訪問公司官網：www.everestmedicines.com。

前瞻性聲明

本新聞稿所發佈的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發佈日後最新信息、未來項目或情形的任何義務，除非法律要求。

成都2026年3月9日 /美通社/ -- 2026年3月9日，四川科倫博泰生物醫藥股份有限公司（「科倫博泰」或「公司」，6990.HK）與和鉑醫藥（股票代碼：02142.HK）宣佈，雙方合作研發的靶向胸腺基質淋巴細胞生成素（TSLP）及一個未公開靶點的長效雙特異性抗體SKB575/HBM7575的新藥臨床試驗（IND）申請已獲中國國家藥品監督管理局（NMPA）批准，用於治療特應性皮炎。

特應性皮炎是一種慢性炎症性皮膚病，以持續性瘙癢、紅斑和皮膚刺激為主要特徵。全球範圍內，該病影響約20%的兒童及高達10%的成人^[1]。雖不具傳染性，但其週期性發作與緩解的疾病特徵嚴重影響了患者的生活品質。當前的治療方案，包括外用皮質類固醇、生物製劑及JAK抑制劑，雖能為許多患者緩解症狀，但往往難以實現長期持續的疾病控制，尤其在中重度患者中更為明顯。因此，行業迫切需要探索更安全、更有效、更持久且能從疾病根本機制入手並改善患者長期預後的治療方案。

科倫博泰首席執行官葛均友博士表示：「很高興看到SKB575/HBM7575獲批開展針對特應性皮炎的臨床試驗，這標誌著我們在自身免疫疾病領域的佈局取得重要進展，可為特應性皮炎患者提供全新的治療選擇。作為一款兼具差異化創新機制與長半衰期優勢的雙特異性抗體，SKB575/HBM7575有望實現持久穩定的疾病控制，並通過降低給藥頻率改善患者的治療體驗。」

和鉑醫藥創始人、董事長兼首席執行官王勁松博士表示：「HBM7575/SKB575獲國家藥監局臨床試驗許可，標誌著我們在應對特應性皮炎等自身免疫疾病的重大臨床需求上，邁出了重要一步。通過靶向2型炎症反應的關鍵上游驅動因數TSLP及未公開靶點，HBM7575/SKB575有望成為該疾病領域同類最佳（best-in-class）的雙特異性抗體。我們期待推進這一在研療法的臨床開發，並相信其長效特性可為全球患者提供差異化的治療選擇。」

[1] https://www.atopicdermatitisatlas.org/en/atopic-dermatitis/how-common-is-atopic-dermatitis

關於SKB575/HBM7575

SKB575/HBM7575是一款靶向胸腺基質淋巴細胞生成素（TSLP）及一個未公開靶點的長效雙特異性抗體，具有雙重作用機制：一方面通過阻斷TSLP與其受體的相互作用，可抑制TSLP介導的信號通路以及Th2免疫細胞的啟動；另一方面，其針對另一未公開靶點的結合與阻斷可產生協同效應，克服TSLP單靶點抗體的耐藥問題。SKB575/HBM7575經過工程化設計，具有延長的半衰期以及良好的可開發性，可實現皮下給藥。基於臨床前半衰期推測，人體半衰期預期可支援3個月以上的給藥間隔，具備同類最佳的潛力。

根據公司與和鉑醫藥之間的合作協定，SKB575/HBM7575由科倫博泰主導設計與全球範圍內的開發及商業化，和鉑醫藥共同參與該專案投資與開發並將按約定共用收益。

關於科倫博泰

四川科倫博泰生物醫藥股份有限公司（簡稱「科倫博泰」，股票代碼：6990.HK）是科倫藥業控股子公司，專注于創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點佈局腫瘤、自身免疫和代謝等重大疾病領域，建設國際化藥物研發與產業化平臺，致力於成為在創新藥物領域國際領先的企業。公司目前擁有30余個重點創新藥項目，其中4個項目8個適應症已獲批上市，1個專案處於NDA階段，10餘個專案正處於臨床階段。公司成功構建了享譽國際的專有ADC及新型偶聯藥物平臺OptiDC^TM，已有2個ADC項目5個適應症獲批上市，多個ADC或新型偶聯藥物產品處於臨床或臨床前研究階段。

關於和鉑醫藥

和鉑醫藥（股票代碼：02142.HK）是一家專注於免疫性疾病及腫瘤領域創新藥研發的全球生物製藥企業。公司通過自主研發、聯合開發及多元化的國際合作模式快速拓展創新藥研發管線。

和鉑醫藥專有的抗體技術平臺Harbour Mice^®能夠生成雙重、雙輕鏈（H2L2）和僅重鏈（HCAb）形式的全人源單克隆抗體。基於HCAb抗體平臺開發的免疫細胞銜接器（HBICE^®）能夠實現傳統藥物聯合療法無法達到的抗腫瘤療效。同時，基於HCAb平臺開發的雙特異性免疫細胞拮抗劑（HBICA^TM）為免疫及炎症性疾病領域創新生物藥的研發提供了有力支援。Harbour Mice^®、HBICE^®、HBICA^TM與單B細胞克隆篩選平臺共同組成了和鉑的下一代創新治療性抗體研發引擎。更多資訊，請訪問：www.harbourbiomed.com。

BARCELONA, Spain, March 9, 2026 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, has secured multiple honors in the GSMA Global Mobile Awards (GLOMO Awards) during MWC Barcelona 2026.

The company won the "Best Private Network Solution" Award, the "Open Gateway Challenge" Award and the "Best Event Activation" Award in recognition of its consistent technological innovation and in-depth industry integration. These achievements fully demonstrate ZTE's leading strengths in open gateway innovation, 5G-A private networks and 5G-A industry scenario-based applications, and its innovative solutions have once again earned high recognition and authoritative affirmation from the global mobile communications industry.

Best Private Network Solution Award: EasyOn 5G-A-RobotNet Solution

The "EasyOn 5G-A-RobotNet" solution, jointly developed by ZTE, China Telecom, intelligent robotics enterprises AGIBOT and DroidUp, has been awarded the "Best Private Network Solution" Award, recognizing the solution as a benchmark for how cellular private networks can transform enterprise operations.

By integrating 5G-Advanced connectivity with embodied intelligence, the winning team has successfully demonstrated how a dedicated, optimized network infrastructure can digitize complex robotic operations and enable flexible, scalable automation in ways previously impossible with public cellular or Wi-Fi. EasyOn 5G-A-RobotNet supports cross-brand robot task orchestration, helping enterprises manage diverse humanoids under a unified system and lowering the overall cost of introducing large-scale robotic operations. Furthermore, the solution enables the real-time acquisition of high-quality multimodal data, facilitating the rapid iteration of embodied AI foundation models.

Open Gateway Challenge Award: AI-Powered Open Gateway Solution

The "AI-Powered Open Gateway" Solution, jointly developed by ZTE, the Network Department of China Mobile Group, China Mobile Hangzhou Research Institute and JD.com, has successfully defended its "Open Gateway Challenge" Award for its cutting-edge technological innovation and benchmark practical value.

Following last year's accolades, China Mobile and ZTE Corporation have continued to innovate. In collaboration with strategic partner JD.com, they have launched an AI-Powered Open Gateway (New AaaS - Abilities as a Service) solution.

Targeting industry customers, this initiative addresses pain points such as the high threshold for invoking CAMARA APIs and low execution efficiency in specific scenarios. Backed by the robust support of ZTE's core network NEF products and the introduction of an API Exposure AI Agent, the solution realizes four major innovations: intent recognition, intelligent orchestration, cross-operator adaptation, and protocol extension. In the collaborative practice, the project has established deep collaboration with JD.com, leveraging core capabilities such as network acceleration (QoD) provided by 5G/5G-A networks to drive innovation in customer service scenarios. By integrating messaging, voice, video, multimedia, and multimodal interaction technologies, the initiative establishes a new paradigm for intelligent customer service, effectively enhancing response efficiency and customer satisfaction. Through the upgrade of the full-domain customer service large model and the construction of a customer service AI data flywheel, this project sets a benchmark for the next-generation intelligent call center industry.

Best Event Activation Award: 5G-A Powered Concert Live Streaming Project

The "5G-A Powered Concert Live Streaming" project, jointly deployed by ZTE, China Telecom and R&J, has won the "Best Event Activation" Award, marking the successful commercialization of 5G-A in the concert live streaming industry and injecting strong momentum into the large-scale transformation of various live streaming scenarios, including event performances, cultural and entertainment activities, and education.

The solution was first implemented at Hangzhou Olympic Sports Center in Zhejiang Province. With excellent performance in concert live broadcast support, it has set a replicable benchmark for the innovation and large-scale application of wireless live streaming in the industry. The 5G-A EasyOn•Live solution achieves a single-camera uplink peak rate of 2Gbps+, paving an efficient channel for high-definition and multi-concurrent live streaming transmission. Equipped with the NodeEngine computing engine, it greatly shortens the data transmission path, ensures transmission security, and enables efficient private network deployment. Supported by 5G-A SuperMIMO technology, it guarantees stable and smooth image transmission even under complex weather conditions such as rain. Compared with the traditional DVB standard solution, the EasyOn•Live solution achieves multiple-camera full coverage, high-definition images and ultra-stability with a single network, without additional expensive hardware equipment, effectively solving the core business pain points of event organizers, and providing a new technical solution for the entire cultural and entertainment live streaming industry.

The annual GLOMO Awards represents the industry's most prestigious accolade. With a judge panel comprising over 200 independent judges, the GLOMO Awards 2026 celebrates individuals and companies that drive innovation and showcase excellence in the rapidly growing mobile industry.

As one of the most prestigious honors in the global mobile communications industry, the GLOMO Awards stand as a strong recognition of ZTE's leadership in open gateway innovation, 5G-A private networks and 5G-A industry scenario-based applications. Going forward, ZTE will continue to deepen cooperation with global operators and industry partners, and build a future-oriented new digital ecosystem with more intelligent, open, and inclusive technological innovations.

For more information, please visit the ZTE booth (3F30, Hall 3, Fira Gran Via) at MWC Barcelona 2026 or explore:
https://www.zte.com.cn/global/about/exhibition/mwc26.html

MEDIA INQUIRIES:
ZTE Corporation
Communications
Email: [email protected]

西班牙巴塞羅那2026年3月9日 /美通社/ -- 當地時間3月4日，2026年世界移動通信大會（MWC26巴塞羅那）期間，GSMA全球移動大獎（GLOMO Awards）評選結果正式揭曉。中興通訊憑借持續的技術創新與深度的行業融合實踐，成功斬獲「最佳專用網絡解決方案獎」、「開放網關挑戰獎」和「最佳活動營銷獎」，充分彰顯了中興通訊5G-A專用網絡賦能具身機器人及大型演唱會直播等行業場景化應用以及在開放網關創新等領域的領先實力，其創新成果再次獲得全球通信行業的高度認可與權威認定。

最佳專用網絡解決方案獎：EasyOn 5G-A-RobotNet解決方案

中興通訊、中國電信聯合打造的 EasyOn 5G-A-RobotNet 解決方案，憑借在5G-A專用網絡與具身智能融合領域的技術突破、商用實踐及產業引領價值，攜手機器人頭部企業智元機器人（AGIBOT）、卓益得機器人（DroidUp）成功斬獲「最佳專用網絡解決方案獎」。方案將5G-Advanced（5G-A）技術與具身智能需求深度融合，編織成一張專屬於人形機器人的網絡，突破傳統公網與Wi-Fi的能力局限。EasyOn 5G-A-RobotNet支持多品牌機器人任務編排，助力企業統一管理多品牌機器人集群，整體降低企業規模化引入機器人作業的成本。同時，該方案可實現高質量多模態數據的實時采集，有利於推動具身智能大模型的快速迭代。

開放網關挑戰獎：AI-Powered Open Gateway解決方案

由中興通訊、中國移動集團網絡事業部、中國移動杭州研發中心與京東集團聯合打造的AI-Powered Open Gateway解決方案，憑借領先的技術創新與標桿實踐價值，斬獲GSMA全球移動大獎（GLOMO）「開放網關挑戰獎」。中國移動和中興通訊繼去年獲獎後，持續創新，聯合京東集團戰略伙伴，針對行業客戶調用CAMARA API的門檻偏高、部分場景執行效率偏低等痛點，利用AI Agent等前沿技術，推出AI-Powered Open Gateway（New AaaS，能力即服務）解決方案，依托中興通訊核心網NEF產品強力支撐，引入API開放智能體，在意圖識別、智能編排、跨網適配、協議擴展四個方面實現創新。在合作實踐中，項目率先與京東集團展開深度協同，依托5G/5G-A網絡提供的網絡加速等核心能力，圍繞客服場景開展創新探索。通過融合消息、語音、視頻、多媒體與多模態交互技術，構建智能化客服新范式，通過客服全域大模型升級，客服AI數據飛輪建設，為行業打造下一代智能呼叫中心的標桿案例。

最佳活動營銷獎：5G-A 賦能無線新模式演唱會直播

中興通訊聯合中國電信和榮澤天韻，憑借「5G-A 賦能無線新模式演唱會直播」項目，榮獲GLOMO獎之「最佳活動營銷獎」，標志著5G-A在演唱會直播行業的成功商用，為賽事展演、文娛活動、教育教學等直播場景注入了規模化轉型的強勁動能。該方案於浙江杭州奧體中心率先落地，憑借其在演唱會直播保障中的卓越表現，為行業無線直播模式革新與規模化推廣打造了可復制的標桿范本。5G-A無線直播方案實現單機位上行峰值速率2Gbps+，為高畫質、多並發傳輸開辟了寬闊平坦的高速路；搭載NodeEngine算力引擎，大幅縮短了傳輸路徑，確保了數據安全，實現高效專網部署；結合5G-A SuperMIMO技術，雨天畫面傳輸依然穩定。相較傳統DVB標准方案，5G-A實現了多機位、高畫質、超穩定的一網覆蓋，無需新增昂貴設備，解決了主辦方的業務痛點，為文娛直播行業帶去了全新選擇。

全球移動大獎（GLOMO）由移動通信行業權威組織GSMA在1996年創辦，擁有200多位獨立評審，是最具權威的通信業獎項，旨在表彰在快速增長的移動行業推動創新並展現出卓越成就的個人和公司。

作為全球移動通信領域最具影響力的行業榮譽，GLOMO大獎是對中興通訊在開放網關創新、5G-A 專用網絡與 5G-A 行業場景化應用領域的充分肯定。未來，中興通訊將持續深化與全球運營商及產業伙伴的合作，以更智能、更開放、更普惠的技術成果，共築面向未來的數字產業新生態。

媒體咨詢:
ZTE Corporation
Communications
Email: [email protected]

The Qingdao Municipal Bureau of Commerce earlier announced that RMB250 million in car trade-in subsidies will be disbursed in March.

Qingdao reportedly launched the "2026 Qingdao New Spring Consumption Season" at the beginning of February.

As of last Thursday (5th), the car trade-in policy has driven total car consumption in the city to reach RMB1.556 billion.
~



AASTOCKS Financial News
Website: www.aastocks.com